National Cancer Institute; Notice of Meeting, 12569-12570 [2020-04297]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 42 / Tuesday, March 3, 2020 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–N–0001]
Preparation for International
Cooperation on Cosmetics Regulation
Fourteenth Annual Meeting; Public
Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public meeting.
The Food and Drug
Administration (FDA or we) is
announcing the following public
meeting entitled ‘‘International
Cooperation on Cosmetics Regulation
(ICCR)—Preparation for ICCR–14
Meeting.’’ The purpose of the public
meeting is to invite public input on
various topics pertaining to the
regulation of cosmetics. We may use
this input to help us prepare for the
ICCR–14 meeting that will be held June
8 to 10, 2020, in Brussels, Belgium.
DATES: The public meeting will be held
on April 14, 2020, from 2 p.m. to 4 p.m.
See the SUPPLEMENTARY INFORMATION
section for registration date and
information.
ADDRESSES: The public meeting will be
held at the Food and Drug
Administration, Center for Food Safety
and Applied Nutrition, 5001 Campus
Dr., Wiley Auditorium (first floor),
College Park, MD 20740. Entrance for
the public meeting participants is
through the Harvey W. Wiley Federal
Building, where routine security check
procedures will be performed.
FOR FURTHER INFORMATION CONTACT:
Deborah Smegal, Office of Cosmetics
and Colors, Food and Drug
Administration, 5001 Campus Dr. (HFS–
100), College Park, MD 20740, 240–402–
1818, Deborah.Smegal@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
lotter on DSKBCFDHB2PROD with NOTICES
SUMMARY:
I. Background
The intention of the ICCR multilateral
framework is to pave the way for the
removal of regulatory obstacles to
international trade while maintaining
global consumer protection. The
purpose of this meeting is to invite
public input on various topics
pertaining to the regulation of
cosmetics. We may use this input to
help us prepare for the ICCR–14 meeting
that will be held June 8 to 10, 2020, in
Brussels, Belgium.
ICCR is a voluntary international
group of cosmetics regulatory
authorities from Brazil, Canada, the
European Union, Japan, and the United
VerDate Sep<11>2014
17:19 Mar 02, 2020
Jkt 250001
States of America. These regulatory
authority members will engage in
constructive dialogue with their
relevant cosmetics industry trade
associations and public advocacy
groups. Currently, the ICCR members
are: The Brazilian Health Surveillance
Agency; Health Canada; the European
Commission Directorate General for
Internal Market, Industry,
Entrepreneurship, and Small and
Medium-sized Enterprises; the Ministry
of Health, Labor, and Welfare of Japan;
and United States Food and Drug
Administration. All decisions are made
by consensus and will be compatible
with the laws, policies, rules,
regulations, and directives of the
respective administrations and
governments. Members will implement
and/or promote actions or documents
within their own jurisdictions and seek
convergence of regulatory policies and
practices. Successful implementation
will need input from stakeholders.
II. Topics for Discussion at the Public
Meeting
We will make the agenda for the
public meeting available by April 7,
2020, on the internet at https://
www.fda.gov/Cosmetics/
InternationalActivities/ICCR/
default.htm.
III. Participating in the Public Meeting
Registration: To register for the public
meeting, send registration information
(including your name, title, affiliation,
address, email, and telephone) to
Deborah Smegal (see FOR FURTHER
INFORMATION CONTACT) by March 31,
2020. If you would like to listen to the
meeting by phone, please submit a
request for a dial-in number by March
31, 2020 (see FOR FURTHER INFORMATION
CONTACT). If you need special
accommodations due to a disability,
please contact Deborah Smegal by April
7, 2020.
Requests for Oral Presentations: If you
wish to present, you should notify
Deborah Smegal by March 31, 2020, and
submit a brief statement of the general
nature of the presentation: What you
wish to present, your name, title,
affiliation, address, email, and
telephone, and indicate the approximate
amount of time needed to make your
presentation. You may wish to present
proposals for future ICCR agenda items,
data, information, or views, in person or
in writing, on issues pending at the
public meeting or a topic related to a
previous meeting. There will be no
presentations by phone. Time allotted
for oral presentations may be limited to
10 minutes or less for each presenter,
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
12569
depending on the number of requests
received.
Transcripts: Please be advised that as
soon as a transcript of the public
meeting is available, it will be accessible
at https://www.regulations.gov. It may
also be viewed at the Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20850.
Dated: February 26, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–04318 Filed 3–2–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Cancer Institute
Council of Research Advocates.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov).
Name of Committee: National Cancer
Institute Council of Research Advocates.
Date: May 11, 2020.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: Welcome and Chairman’s
Remarks, NCI Updates, Legislative Update,
and Director’s Update.
Place: National Institutes of Health, 40
Convent Drive, Building 40, Room 1201/1203
Bethesda, MD 20892.
Contact Person: Amy Williams, NCI Office
of Advocacy Relations, National Cancer
Institute, NIH, 31 Center Drive, Building 31,
Room 10A28, Bethesda, MD 20892, 240–781–
3360, williaam@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
E:\FR\FM\03MRN1.SGM
03MRN1
12570
Federal Register / Vol. 85, No. 42 / Tuesday, March 3, 2020 / Notices
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: NCRA: https://
deainfo.nci.nih.gov/advisory/ncra/ncra.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 26, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–04297 Filed 3–2–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
lotter on DSKBCFDHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Interdisciplinary Molecular
Sciences and Training.
Date: March 25, 2020.
Time: 10:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Lystranne Alysia Maynard
Smith, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–402–4809,
lystranne.maynard-smith@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel PAR Panel:
VerDate Sep<11>2014
17:19 Mar 02, 2020
Jkt 250001
Opioids and HIV at the Single Cell, Single
RNA Level.
Date: March 26, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Nuria E Assa-Munt, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164,
MSC 7806, Bethesda, MD 20892, (301) 451–
1323, assamunu@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Fellowships:
Cardiovascular and Respiratory Sciences.
Date: March 26–27, 2020.
Time: 8:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard Silver Spring Downtown,
8506 Fenton Street, Silver Spring, MD 20910.
Contact Person: Kimm Hamann, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118A,
MSC 7814, Bethesda, MD 20892, 301–435–
5575, hamannkj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Cellular and Molecular
Immunology.
Date: March 26, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Deborah Hodge, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4207,
MSC 7812, Bethesda, MD 20892, (301) 435–
1238, hodged@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel PAR Panel:
Opioids and HIV at the Biological, Single
RNA Level.
Date: March 26, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Nuria E Assa-Munt, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4164,
MSC 7806, Bethesda, MD 20892, (301) 451–
1323, assamunu@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Small
Business: Microbial (non-HIV) Diagnostics
and Detection of Infectious Agents, Food and
Waterborne Pathogens, and Methods in
Microbial Sterilization, Disinfection and
Bioremediation.
Date: March 26–27, 2020.
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton, 940 Rose Avenue,
North Bethesda, MD 20852.
Contact Person: Gagan Pandya, Ph.D.
Scientific Review Officer, National Institutes
of Health, Center for Scientific Review, 6701
Rockledge Drive, RM 3200, MSC 7808,
Bethesda, MD 20892, 301–435–1167,
pandyaga@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Vaccines, Host Defense,
Inflammation and Immunity.
Date: March 26, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Andrea Keane-Myers,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4218,
Bethesda, MD 20892, 301–435–1221,
andrea.keane-myers@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel RFA–NS18–
041: Discovery of Heal-Biomarkers for Pain.
Date: March 26, 2020.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joseph G. Rudolph, Ph.D.,
Chief and Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7844 Bethesda, MD 20892, 301–408–
9098, josephru@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel PAR Panel:
Pediatric and Obstetric Pharmacology and
Therapeutics.
Date: March 26, 2020.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dianne Hardy, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6175,
MSC 7892, Bethesda, MD 20892, 301–435–
1154, dianne.hardy@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Member
Conflict: Biological Chemistry and
Macromolecular Biophysics.
Date: March 26–27, 2020.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sergei Ruvinov, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
E:\FR\FM\03MRN1.SGM
03MRN1
]]>Agencies
[Federal Register Volume 85, Number 42 (Tuesday, March 3, 2020)]
[Notices]
[Pages 12569-12570]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-04297]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Cancer
Institute Council of Research Advocates.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting. The open session will be videocast and can be
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov).
Name of Committee: National Cancer Institute Council of Research
Advocates.
Date: May 11, 2020.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: Welcome and Chairman's Remarks, NCI Updates, Legislative
Update, and Director's Update.
Place: National Institutes of Health, 40 Convent Drive, Building
40, Room 1201/1203 Bethesda, MD 20892.
Contact Person: Amy Williams, NCI Office of Advocacy Relations,
National Cancer Institute, NIH, 31 Center Drive, Building 31, Room
10A28, Bethesda, MD 20892, 240-781-3360, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a
[[Page 12570]]
government-issued photo ID, driver's license, or passport) and to
state the purpose of their visit.
Information is also available on the Institute's/Center's home
page: NCRA: https://deainfo.nci.nih.gov/advisory/ncra/ncra.htm, where
an agenda and any additional information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 26, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-04297 Filed 3-2-20; 8:45 am]
BILLING CODE 4140-01-P
